- Home
- ASA vs URGN Comparison
ASA vs URGN Comparison
Compare ASA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- URGN
- Stock Information
- Founded
- ASA 1958
- URGN 2004
- Country
- ASA United States
- URGN United States
- Employees
- ASA N/A
- URGN N/A
- Industry
- ASA Precious Metals
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- ASA Industrials
- URGN Health Care
- Exchange
- ASA Nasdaq
- URGN Nasdaq
- Market Cap
- ASA 549.0M
- URGN 463.2M
- IPO Year
- ASA N/A
- URGN 2017
- Fundamental
- Price
- ASA $28.26
- URGN $9.87
- Analyst Decision
- ASA
- URGN Strong Buy
- Analyst Count
- ASA 0
- URGN 7
- Target Price
- ASA N/A
- URGN $36.75
- AVG Volume (30 Days)
- ASA 79.6K
- URGN 711.3K
- Earning Date
- ASA 05-30-2025
- URGN 05-12-2025
- Dividend Yield
- ASA 0.18%
- URGN N/A
- EPS Growth
- ASA N/A
- URGN N/A
- EPS
- ASA 11.67
- URGN N/A
- Revenue
- ASA $3,557,386.00
- URGN $91,871,000.00
- Revenue This Year
- ASA N/A
- URGN $36.05
- Revenue Next Year
- ASA N/A
- URGN $114.54
- P/E Ratio
- ASA $2.47
- URGN N/A
- Revenue Growth
- ASA 45.39
- URGN 8.98
- 52 Week Low
- ASA $16.97
- URGN $8.94
- 52 Week High
- ASA $31.94
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- ASA 45.49
- URGN 45.00
- Support Level
- ASA $29.92
- URGN $9.71
- Resistance Level
- ASA $30.85
- URGN $11.73
- Average True Range (ATR)
- ASA 0.83
- URGN 1.06
- MACD
- ASA -0.28
- URGN -0.06
- Stochastic Oscillator
- ASA 7.54
- URGN 10.68
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.